Skip to main content
Back to timeline
AignosticsSource publication:

HETA widens spatial H&E readouts to immune phenotyping and mitosis, ranking lymphocyte density in tumor core and margin against a pan-cancer TCGA reference

Synopsis

Aignostics updated HETA, its spatial H&E analysis platform, adding immune phenotyping readouts, tumor-infiltrating lymphocyte analysis, mitosis detection, and nerve and fat segmentation. Immune phenotyping measures lymphocyte density in the tumor core and at its margins separately, each ranked against a pan-cancer TCGA reference, as continuous values rather than one label per slide, so researchers can set their own inflamed, excluded and desert thresholds. The platform also outputs counts and densities of mature and immature tertiary lymphoid structures and extends tissue segmentation to 9 classes, as the basis for future perineural invasion readouts.

Source-provided article image: Aignostics Expands the Breadth and Depth of Spatial H&E Analysis in HETA
Aignostics

Interpretation

The update extends HETA's readouts from tissue segmentation to immune and proliferation measures: immune phenotyping, tumor-infiltrating lymphocytes, mitosis detection, and nerve and fat segmentation. HETA previously detected tertiary lymphoid structures, but the number and location of immune cells, tumor proliferation rate, and the prognosis-linked nerve and fat tissues were not reported as separate readouts. The immune phenotyping readouts measure lymphocyte density in the tumor core and at its margins separately, each ranked against a pan-cancer TCGA reference to show whether immune infiltration is high or low relative to other tumors.

These readouts are delivered as continuous values and exportable quantitative results rather than one category label per slide. The platform reports continuous values rather than a single label per slide, so the inflamed, excluded and desert thresholds are set by the researcher. Outputs arrive as overlays in the Aignostics pathology viewer or the user's own image management system, plus exportable quantitative readouts.

The new readouts map to two uses in clinical development: selecting likely responders to checkpoint inhibitors and stratifying prognosis by immune response and tumor proliferation. Tumor-infiltrating lymphocytes and mitotic activity are two established prognostic factors on H&E, reflecting immune response and tumor proliferation respectively. The TIL readout covers lymphocyte density in tumor stroma and carcinoma, the ratio between them, and a combined score for the tumor core and invasive margin; mitotic activity is reported as both a count and an index across all carcinoma cells on the slide.

Perspective

The readouts are intended for life sciences research, and the material marks them for research use only, not for diagnostic procedures; the demonstrated settings are patient selection and prognostic stratification in clinical development, with validation metrics available on request.

The material describes HETA as one of the more comprehensive platforms for H&E analysis in feature breadth and spatial depth but gives no comparison data against other platforms; nerve segmentation is only the basis for a future perineural invasion readout, which is not yet provided.